HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

NCT07459673 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-positive Breast Cancer
Breast Cancer Stage IV

Interventions

DIAGNOSTIC_TEST: Personalis NeXT Personal
DIAGNOSTIC_TEST: Natera Signatera
BIOLOGICAL: Trastuzumab deruxtecan-nxki

Sponsor

Memorial Sloan Kettering Cancer Center